Who was studied?
Chinese adults with overweight plus a weight-related condition, or obesity; mean baseline BMI was 33.1 kg/m². Participants received weekly UBT251 or placebo.
- Participants
- 205 Chinese adults
- Duration
- 24 weeks
- Funding
- TUL / United Biotechnology; company employee and shareholding disclosures in the abstract
What did the study find?
The 4 mg target arm starting at 1 mg had 19.7% least-squares mean weight loss, versus 2.0% with placebo. The other 4 mg starting-dose arm had 16.2%; the 6 mg arm had 18.7%.
What should you keep in mind?
A conference abstract with less detail than a full trial report. Gastrointestinal events were most frequent, mainly mild to moderate. Differences between arms do not prove an optimal personal dose.
Why it matters
Keep the starting-dose arm, population and 24-week endpoint beside the headline. This was not a head-to-head Retatrutide comparison.
3090-LB: UBT251, a Triple Hormone Receptor Agonist in Adults with Overweight or Obesity: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Trial
Published 2026 · DOI 10.2337/db26-3090-LB
Summary by Peptide Lit, checked against the original abstract on October 9, 2026. A conference abstract provides limited methods and safety detail; follow the original source for later reports. This page explains published research; it does not recommend a treatment or dose.